PXS-6302 is an irreversiblelysyl oxidaseinhibitor withIC₅₀s of 3.7 μM (Bovine LOX), 3.4 μM (rh LOXL1), 0.4 μM (rh LOXL2), 1.5 μM (rh LOXL3), 0.3 μM (rh LOXL4), respectively. PXS-6302 has readily skin penetrability, reduces collagen deposition and significantly improves scar appearance^[1].

3.7 μM (Bovine LOX), 3.4 μM (rh LOXL1), 0.4 μM (rh LOXL2), 1.5 μM (rh LOXL3), 0.3 μM (rh LOXL4)^[1]

PXS-6302 demonstrates high permeability to across a monolayer of cells, such as Caco-2 or MDCKII cells^[1].

PXS-6302 inhibits LOX, reduces crosslinking and improves scar appearance in porcine models of excisional and burn injury^[1].
PXS-6302 (1.5%, oil in water cream; 500 mg cream applied to 16 cm²; external application; once daily, for 28 days) reduces collagen deposition and cross-linkin in murine models of injury and fibrosis under topical application^[1].
PXS-6302 (0.5, 1.5, or 3%, oil in water cream; 400 mg cream applied to 16 cm²; external application; once daily, for 12 weeks) also significantly improves scar appearance without reducing tissue strength in porcine injury models under topical application^[1].

265.25

C₁₀H₁₀F₃NO₂S

2584947-54-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.